Specialty pharmaceutical company developing therapies for critical care and cancer supportive care.
Citius Pharmaceuticals, Inc. is a dynamic late-stage pharmaceutical company dedicated to advancing critical care solutions across several therapeutic areas. Specializing in oncology products, anti-infectives for adjunct cancer care, prescription medications, and stem cell therapies, Citius Pharmaceuticals is at the forefront of developing innovative treatments to address unmet medical needs.
The company's robust pipeline includes five proprietary products poised to transform patient care. Among these are I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein designed to treat patients with persistent or recurrent cutaneous T-cell lymphoma. Additionally, Citius Pharmaceuticals is advancing Mino-Lok, an antibiotic lock solution aimed at salvaging infected catheters and treating catheter-related bloodstream infections.
Citius Pharmaceuticals is also developing Halo-Lido, a corticosteroid-lidocaine topical formulation intended to provide effective anti-inflammatory and anesthetic relief for individuals suffering from hemorrhoids. Another promising product in its portfolio is Mino-Wrap, a gel-based wrap designed to reduce infections associated with tissue expanders following breast reconstructive surgeries. Furthermore, the company is exploring NoveCite, a mesenchymal stem cell therapy targeting acute respiratory distress syndrome.
Founded in 2007 and headquartered in Cranford, New Jersey, Citius Pharmaceuticals combines cutting-edge research with a commitment to improving patient outcomes. With a strong emphasis on innovation and clinical advancement, the company continues to expand its portfolio of therapeutic solutions, addressing critical medical challenges globally.